Vittorio Branchi
Overview
Explore the profile of Vittorio Branchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Branchi V, Hosni R, Kiwitz L, Ng S, van der Voort G, Bambi N, et al.
Hum Pathol
. 2024 Oct;
153:105670.
PMID: 39406289
Biliary tract cancers (BTC) are rare lethal malignancies arising along the biliary tree. Unfortunately, effective therapeutics are lacking and the prognosis remains dismal even for patients eligible for surgical resection....
2.
Bahrambeigi V, Lee J, Branchi V, Rajapakshe K, Xu Z, Kui N, et al.
Cancer Res
. 2024 Mar;
84(10):1719-1732.
PMID: 38451249
Significance: The development of an approach to interrogate molecular subtypes, cancer-associated pathways, and differentially expressed genes through RNA sequencing of plasma extracellular vesicles lays the foundation for liquid biopsy-based longitudinal...
3.
Kania A, Branchi V, Braun L, Verrel F, Kalff J, Vilz T
Chirurgie (Heidelb)
. 2024 Feb;
95(5):367-374.
PMID: 38378936
Acute mesenteric ischemia (AMI) is still a time-critical and life-threatening clinical picture. If exploration of the abdominal cavity is necessary during treatment, an intraoperative assessment of which segments of the...
4.
Dold L, Frank L, Lutz P, Kaczmarek D, Kramer B, Nattermann J, et al.
Clin Transl Gastroenterol
. 2023 May;
14(8):e00603.
PMID: 37256725
Introduction: Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with periductal inflammation and fibrosis. Genetic studies suggest inflammatory cytokines and IL-6-dependent activation of transcription factor STAT3 as pivotal...
5.
Kolbinger F, Bernard V, Lee J, Stephens B, Branchi V, Raghav K, et al.
J Gastrointest Cancer
. 2023 Mar;
54(4):1276-1285.
PMID: 36862364
Purpose: Cancer of unknown primary (CUP) accounts for 2-5% of all cancer diagnoses, wherein standard investigations fail to reveal the original tumor site. Basket trials allocate targeted therapeutics based on...
6.
Kramer B, Nalin A, Ma F, Eickhoff S, Lutz P, Leonardelli S, et al.
Cell Rep
. 2023 Jan;
42(1):111937.
PMID: 36640314
Group 1 innate lymphoid cells (ILCs) comprise a heterogeneous family of cytotoxic natural killer (NK) cells and ILC1s. We identify a population of "liver-type" ILC1s with transcriptional, phenotypic, and functional...
7.
Henn J, Wyzlic P, Esposito I, Semaan A, Branchi V, Klinger C, et al.
Langenbecks Arch Surg
. 2023 Jan;
408(1):28.
PMID: 36640188
Purpose: The detection of pancreatic cystic lesions (PCL) causes uncertainty for physicians and patients, and international guidelines are based on low evidence. The extent and perioperative risk of resections of...
8.
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, et al.
Diagnostics (Basel)
. 2022 Jun;
12(6).
PMID: 35741223
Background: Despite the significance of colonoscopy for early diagnosis of colorectal adenocarcinoma (CRC), population-wide screening remains challenging, mainly because of low acceptance rates. Herein, exosomal (exo-miR) and free circulating microRNA...
9.
Esser L, Branchi V, Shakeri F, Simon A, Stephan C, Kristiansen G, et al.
Int J Oncol
. 2022 Jan;
60(2).
PMID: 35059737
Low expression levels of the E3 ubiquitin‑protein ligase Parkin (PARK2) are exhibited in several cancer entities, including clear cell renal cell carcinoma (ccRCC), and are associated with poor prognosis; however,...
10.
Gonzalez-Carmona M, Mohring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, et al.
Sci Rep
. 2022 Jan;
12(1):1011.
PMID: 35046437
Prognosis of patients with advanced extrahepatic cholangiocarcinoma (eCCA) is poor. The current standard first-line treatment is systemic chemotherapy (CT) with gemcitabine and a platinum derivate. Additionally, endobiliary radiofrequency ablation (eRFA)...